Serum FLT-3 ligand in a busulphan-induced model of chronic bone marrow hypoplasia in the female CD-1 mouse

International Journal of Experimental Pathology

Volumn 89, Issue 2, 2008, Pages 159-170

  Molyneux, Gemma ^a,b,d   Gibson, Frances M ^a   Whayman, Matthew ^c   Turton, John A ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Aplasia; Bone marrow; Busulphan; fms like tyrosine kinase 3 ligand; Hypoplasia; Mouse

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BUSULFAN; CYTOKINE; FLT3 LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BLOOD CELL COUNT; BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW CELL; BONE MARROW DEPRESSION; BONE MARROW DISEASE; BONE MARROW HYPOPLASIA; CELL SUSPENSION; COLONY FORMING UNIT; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; LINEAR REGRESSION ANALYSIS; MOUSE; MOUSE STRAIN; NONHUMAN; OUTBRED STRAIN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOOD CELL COUNT; BODY WEIGHT; BONE MARROW CELLS; BONE MARROW DISEASES; BUSULFAN; CHRONIC DISEASE; COLONY-FORMING UNITS ASSAY; DISEASE MODELS, ANIMAL; FEMALE; HEMATOPOIETIC STEM CELLS; IMMUNOSUPPRESSIVE AGENTS; MEMBRANE PROTEINS; MICE; PANCYTOPENIA;

EID: 40549087651     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/j.1365-2613.2008.00580.x     Document Type: Article

References (35)

1. Anderson R.W., Matthews K.I., Crouse D.A. et al. (1982) In vitro evaluation of hematopoiesis in mice treated with busulphan or nitrogen mustard. Biomed. Pharmacother. 36, 149 152.
2. Bertho J.M., Demarquay C., Frick J. et al. (2001) Level of FLT3-ligand in plasma: a possible new bio-indicator for radiation-induced aplasia. Int. J. Radiat. Biol. 77, 703 712.
3. Blumenthal R.D., Lew W., Juweid M. et al. (2000) Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy. Cancer 88, 333 343.
4. BNF (2004) British National Formulary. London : British Medical Association.
5. Boggs D.R. Boggs S.S. (1980) The effect of graded, single doses of busulfan on murine erythropoiesis. Proc. Soc. Exp. Biol. Med. 163, 181 186.
6. Brasel K., McKenna H.J., Morrissey P.J. (1996) Hematologic effects of flt3 ligand in vivo in mice. Blood 88, 2004 2012.
7. Bright R., Eisendrath S., Damen L. (2001) A case of factitious aplastic anemia. Int. J. Psychiatry Med. 31, 433 441.
8. Buggia I., Locatelli F., Zecca M. (1994) Busulphan. Ann. Pharmacother. 28, 1055 1062.
9. Charles River (2005) Product Information. http://www.criver.com.
10. Chklovskaia E., Jansen W., Nissen C. et al. (1999) Mechanism of FLT-3 ligand expression in bone marrow failure: translocation from intracellular stores to the surface of T lymphocytes after chemotherapy-induced suppression of hematopoiesis. Blood 93, 2595 2604.
11. Dollery C. (1999) Therapeutic Drugs, 3rd edn. Edinburgh : Churchill Livingstone.
12. Dunn C.D.R. Elson L.A. (1970) The comparative effect of busulphan ('Myleran') and aminochlorambucil on haemopoietic colony forming units in the rat. Cell Tissue Kinet. 3, 131 141.
13. Gibson F.M., Andrews C.M., Diamanti P. et al. (2003) A new model of busulphan-induced chronic bone marrow aplasia in the female BALB/c mouse. Int. J. Exp. Pathol. 84, 31 48.
14. Gratwohl A., John L., Baldomero H. et al. (1998) FLT-3 ligand provides hematopoietic protection from total body irradiation in rabbits. Blood 92, 765 769.
15. Home Office (1989) Home Office Code of Practice for the Housing and Care of Animals Used in Scientific Procedures. London : Her Majesty's Stationery Office.
16. Huchet A., Belkacemi Y., Frick J. et al. (2003) Plasma Flt-3 ligand concentration correlated with radiation-induced bone marrow damage during local fractionated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 57, 508 515.
17. Jopling C. Rosendaal M. (2001) A cautionary tale: how to delete mouse haemopoietic stem cells with busulphan. Br. J. Haematol. 113, 970 974.
18. Lyman S.D., Seaberg M., Hanna R. et al. (2005) Plasma/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia. Blood 86, 4091 4096.
19. McKenna H.J., Stocking K.L., Miller R.E. et al. (2000) Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 95, 3489 3497.
20. Molyneux G., Rizzo S., Gibson F.M. et al. (2004) Haemotoxicity of chlorambucil in the Wistar Hanover rat with particular reference to bone marrow culture, marrow cell apoptosis and levels of FLT-3 ligand. Comp. Clin. Pathol. 13, 70 81.
21. Molyneux G., Gibson F.M., Gordon-Smith E.C. et al. (2005) The haemotoxicity of mitomycin in a repeat dose study in the female CD-1 mouse. Int. J. Exp. Pathol. 86, 415 430.
22. Morley A. Blake J. (1974a) An animal model of chronic hypoplastic marrow failure. I. Late marrow failure after busulphan. Blood 44, 49 56.
23. Morley A. Blake J. (1974b) Hemopoietic precursor cells in experimental hypoplastic marrow failure. Aust. J. Exp. Biol. Med. Sci. 52, 909 914.
24. Morley A., Trainor K., Blake J. (1975) A primary stem cell lesion in experimental chronic hypoplastic marrow failure. Blood 45, 681 688.
25. Morley A.A., Trainor K.J., Seshadri R.S. (1978) Chronic hypoplastic marrow failure and residual injury. Blood Cells 4, 253 265.
26. Pfister O., Chklovskaia E., Jansen W. et al. (2001) Chronic overexpression of membrane-bound flt3 ligand by T lymphocytes in severe aplastic anaemia. Br. J. Haematol. 109, 211 220.
27. Prat M., Demarquay C., Frick J. et al. (2005) Radiation-induced increase in plasma Flt3 ligand concentration in mice: evidence for the implication of several cell types. Radiat. Res. 163, 408 417.
28. Pugsley C.A.J., Forbes I.J., Morley A.A. (1978) Immunologic abnormalities in an animal model of chronic hypoplastic marrow failure induced by busulphan. Blood 51, 601 610.
29. Rosnet O., Buhring H.J., deLapeyriere O. et al. (1996) Expression and signal transduction of the FLT3 tyrosine kinase receptor. Acta Haematol. 95, 218 223.
30. Santos G.W. Tutschka P.J. (1974) Marrow transplantation in the busulfan-treated rat: preclinical model of aplastic anemia. J. Natl. Cancer Inst. 53, 1781 1785.
31. Sweetman S.C. (2002) Martindale: The Complete Drug Reference, 33rd edn. London : Pharmaceutical Press.
32. Trainor K.J., Seshadri R.S., Morley A.A. (1979) Residual marrow injury following cytotoxic drugs. Leuk. Res. 3, 205 210.
33. Turton J.A., Sones W.R., Andrews C.M. et al. (2006) Further development of a model of chronic bone marrow aplasia in the busulphan-treated mouse. Int. J. Exp. Pathol. 87, 49 63.
34. Vollstedt S., Franchini M., Hefti H.P. et al. (2003) Flt3 ligand-treated neonatal mice have increased innate immunity against intracellular pathogens and efficiently control virus infections. J. Exp. Med. 197, 575 584.
35. Wodnar-Filipowicz A., Lyman S.D., Gratwohl A. et al. (1996) Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia. Blood 88, 4493 4499.